Robert Hawkins
Chief Tech/Sci/R&D Officer chez INSTIL BIO, INC.
Fortune : 31 977 $ au 31/03/2024
Profil
Robert Edward Hawkins is the founder of Instil Bio (UK) Ltd.
He currently holds the position of Head-Research & Development at Instil Bio, Inc. and Independent Non-Executive Director at BiVictriX Therapeutics Plc.
In the past, he served as a Director at Instil Bio, Inc. and as an Independent Non-Executive Director at Motif Bio Plc.
He was also an Honorary Professor at The University of Manchester.
Hawkins received his undergraduate and doctorate degrees from the University of Cambridge and his doctorate degree from University College London.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/12/2022 | 225 000 ( 0,27% ) | 31 977 $ | 31/03/2024 |
Postes actifs de Robert Hawkins
| Sociétés | Poste | Début |
|---|---|---|
| BIVICTRIX THERAPEUTICS PLC | Director/Board Member | 22/09/2021 |
| INSTIL BIO, INC. | Chief Tech/Sci/R&D Officer | 11/11/2022 |
Anciens postes connus de Robert Hawkins
| Sociétés | Poste | Fin |
|---|---|---|
| INSTIL BIO, INC. | Director/Board Member | 01/07/2020 |
| Instil Bio (UK) Ltd. | Chief Executive Officer | 01/01/2020 |
| The University of Manchester | Corporate Officer/Principal | - |
| MOTIF BIO PLC | Director/Board Member | - |
Formation de Robert Hawkins
| University of Cambridge | Doctorate Degree |
| University College London | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BIVICTRIX THERAPEUTICS PLC | Health Technology |
| INSTIL BIO, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
| Instil Bio (UK) Ltd. | |
Motif Bio Plc
 Motif Bio Plc Pharmaceuticals: MajorHealth Technology Motif Bio Plc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of pharmaceutical formulations. The company focuses on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. It offers Iclaprim, a novel diaminopyrimidine antibiotic that inhibits an essential bacterial enzyme called dihydrofolate reductase. The company was founded by Jonathan E. Gold on November 20, 2014 and is headquartered in Princeton, NJ. | Health Technology |
